Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial-Reference-Cited by-同舟云学术

Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial

Published:2022-02 Issue: Volume:162 Page:45-55
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Peuker Caroline A.^ORCID,Yaghobramzi Sarvenaz,Grunert Corinna^ORCID,Keilholz Luisa,Gjerga Enio,Hennig Steffen,Schaper Sigrid,Na Il-Kang,Keller Ulrich,Brucker Sara^ORCID,Decker Thomas,Fasching Peter,Fehm Tanja,Janni Wolfgang,Kümmel Sherko^ORCID,Schneeweiss Andreas,Schuler Martin^ORCID,Lüftner Diana^ORCID,Busse Antonia^ORCID

Funder

Novartis Pharma

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Overall survival with ribociclib plus fulvestrant in advanced breast cancer;Slamon;N Engl J Med,2020

2. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial;Sledge;JAMA Oncol,2020

3. Overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner;N Engl J Med,2018

4. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat Rev Drug Discov,2015

5. Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice;McCartney;Front Oncol,2019

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer;International Immunopharmacology;2024-12

2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

3. Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer;Cells;2024-08-21

4. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients;British Journal of Radiology;2024-08-09

5. Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data;Pharmaceuticals;2024-07-11